Summary
According to APO Research, The global Biosimilar market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Biosimilar include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Biosimilar, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biosimilar, also provides the revenue of main regions and countries. Of the upcoming market potential for Biosimilar, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biosimilar revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biosimilar market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Biosimilar revenue, projected growth trends, production technology, application and end-user industry.
Biosimilar segment by Company
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Biosimilar segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Biosimilar segment by Application
Cancer
Immunological Diseases
Diabetes
Others
Biosimilar segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Biosimilar in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Biosimilar company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilar revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Biosimilar Market by Type
1.2.1 Global Biosimilar Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Biosimilar Monoclonal Antibodies
1.2.3 Biosimilar Insulin
1.2.4 Others
1.3 Biosimilar Market by Application
1.3.1 Global Biosimilar Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Immunological Diseases
1.3.4 Diabetes
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Biosimilar Market Dynamics
2.1 Biosimilar Industry Trends
2.2 Biosimilar Industry Drivers
2.3 Biosimilar Industry Opportunities and Challenges
2.4 Biosimilar Industry Restraints
3 Global Growth Perspective
3.1 Global Biosimilar Market Perspective (2019-2030)
3.2 Global Biosimilar Growth Trends by Region
3.2.1 Global Biosimilar Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Biosimilar Market Size by Region (2019-2024)
3.2.3 Global Biosimilar Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Biosimilar Revenue by Players
4.1.1 Global Biosimilar Revenue by Players (2019-2024)
4.1.2 Global Biosimilar Revenue Market Share by Players (2019-2024)
4.1.3 Global Biosimilar Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Biosimilar Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Biosimilar Key Players Headquarters & Area Served
4.4 Global Biosimilar Players, Product Type & Application
4.5 Global Biosimilar Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Biosimilar Market CR5 and HHI
4.6.2 Global Top 5 and 10 Biosimilar Players Market Share by Revenue in 2023
4.6.3 2023 Biosimilar Tier 1, Tier 2, and Tier 3
5 Biosimilar Market Size by Type
5.1 Global Biosimilar Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Biosimilar Revenue by Type (2019-2030)
5.3 Global Biosimilar Revenue Market Share by Type (2019-2030)
6 Biosimilar Market Size by Application
6.1 Global Biosimilar Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Biosimilar Revenue by Application (2019-2030)
6.3 Global Biosimilar Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Qilu Pharmaceutical
7.1.1 Qilu Pharmaceutical Comapny Information
7.1.2 Qilu Pharmaceutical Business Overview
7.1.3 Qilu Pharmaceutical Biosimilar Revenue and Gross Margin (2019-2024)
7.1.4 Qilu Pharmaceutical Biosimilar Product Portfolio
7.1.5 Qilu Pharmaceutical Recent Developments
7.2 Bio-Thera
7.2.1 Bio-Thera Comapny Information
7.2.2 Bio-Thera Business Overview
7.2.3 Bio-Thera Biosimilar Revenue and Gross Margin (2019-2024)
7.2.4 Bio-Thera Biosimilar Product Portfolio
7.2.5 Bio-Thera Recent Developments
7.3 Zhejiang Hisun
7.3.1 Zhejiang Hisun Comapny Information
7.3.2 Zhejiang Hisun Business Overview
7.3.3 Zhejiang Hisun Biosimilar Revenue and Gross Margin (2019-2024)
7.3.4 Zhejiang Hisun Biosimilar Product Portfolio
7.3.5 Zhejiang Hisun Recent Developments
7.4 Shanghai Henlius
7.4.1 Shanghai Henlius Comapny Information
7.4.2 Shanghai Henlius Business Overview
7.4.3 Shanghai Henlius Biosimilar Revenue and Gross Margin (2019-2024)
7.4.4 Shanghai Henlius Biosimilar Product Portfolio
7.4.5 Shanghai Henlius Recent Developments
7.5 Innovent Biologics
7.5.1 Innovent Biologics Comapny Information
7.5.2 Innovent Biologics Business Overview
7.5.3 Innovent Biologics Biosimilar Revenue and Gross Margin (2019-2024)
7.5.4 Innovent Biologics Biosimilar Product Portfolio
7.5.5 Innovent Biologics Recent Developments
7.6 Jiangsu Hengrui
7.6.1 Jiangsu Hengrui Comapny Information
7.6.2 Jiangsu Hengrui Business Overview
7.6.3 Jiangsu Hengrui Biosimilar Revenue and Gross Margin (2019-2024)
7.6.4 Jiangsu Hengrui Biosimilar Product Portfolio
7.6.5 Jiangsu Hengrui Recent Developments
7.7 Gan&Lee
7.7.1 Gan&Lee Comapny Information
7.7.2 Gan&Lee Business Overview
7.7.3 Gan&Lee Biosimilar Revenue and Gross Margin (2019-2024)
7.7.4 Gan&Lee Biosimilar Product Portfolio
7.7.5 Gan&Lee Recent Developments
7.8 Tonghua Dongbao
7.8.1 Tonghua Dongbao Comapny Information
7.8.2 Tonghua Dongbao Business Overview
7.8.3 Tonghua Dongbao Biosimilar Revenue and Gross Margin (2019-2024)
7.8.4 Tonghua Dongbao Biosimilar Product Portfolio
7.8.5 Tonghua Dongbao Recent Developments
7.9 United Laboratory
7.9.1 United Laboratory Comapny Information
7.9.2 United Laboratory Business Overview
7.9.3 United Laboratory Biosimilar Revenue and Gross Margin (2019-2024)
7.9.4 United Laboratory Biosimilar Product Portfolio
7.9.5 United Laboratory Recent Developments
7.10 3SBIO
7.10.1 3SBIO Comapny Information
7.10.2 3SBIO Business Overview
7.10.3 3SBIO Biosimilar Revenue and Gross Margin (2019-2024)
7.10.4 3SBIO Biosimilar Product Portfolio
7.10.5 3SBIO Recent Developments
7.11 Luye Pharma
7.11.1 Luye Pharma Comapny Information
7.11.2 Luye Pharma Business Overview
7.11.3 Luye Pharma Biosimilar Revenue and Gross Margin (2019-2024)
7.11.4 Luye Pharma Biosimilar Product Portfolio
7.11.5 Luye Pharma Recent Developments
8 North America
8.1 North America Biosimilar Revenue (2019-2030)
8.2 North America Biosimilar Revenue by Type (2019-2030)
8.2.1 North America Biosimilar Revenue by Type (2019-2024)
8.2.2 North America Biosimilar Revenue by Type (2025-2030)
8.3 North America Biosimilar Revenue Share by Type (2019-2030)
8.4 North America Biosimilar Revenue by Application (2019-2030)
8.4.1 North America Biosimilar Revenue by Application (2019-2024)
8.4.2 North America Biosimilar Revenue by Application (2025-2030)
8.5 North America Biosimilar Revenue Share by Application (2019-2030)
8.6 North America Biosimilar Revenue by Country
8.6.1 North America Biosimilar Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Biosimilar Revenue by Country (2019-2024)
8.6.3 North America Biosimilar Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Biosimilar Revenue (2019-2030)
9.2 Europe Biosimilar Revenue by Type (2019-2030)
9.2.1 Europe Biosimilar Revenue by Type (2019-2024)
9.2.2 Europe Biosimilar Revenue by Type (2025-2030)
9.3 Europe Biosimilar Revenue Share by Type (2019-2030)
9.4 Europe Biosimilar Revenue by Application (2019-2030)
9.4.1 Europe Biosimilar Revenue by Application (2019-2024)
9.4.2 Europe Biosimilar Revenue by Application (2025-2030)
9.5 Europe Biosimilar Revenue Share by Application (2019-2030)
9.6 Europe Biosimilar Revenue by Country
9.6.1 Europe Biosimilar Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Biosimilar Revenue by Country (2019-2024)
9.6.3 Europe Biosimilar Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Biosimilar Revenue (2019-2030)
10.2 China Biosimilar Revenue by Type (2019-2030)
10.2.1 China Biosimilar Revenue by Type (2019-2024)
10.2.2 China Biosimilar Revenue by Type (2025-2030)
10.3 China Biosimilar Revenue Share by Type (2019-2030)
10.4 China Biosimilar Revenue by Application (2019-2030)
10.4.1 China Biosimilar Revenue by Application (2019-2024)
10.4.2 China Biosimilar Revenue by Application (2025-2030)
10.5 China Biosimilar Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Biosimilar Revenue (2019-2030)
11.2 Asia Biosimilar Revenue by Type (2019-2030)
11.2.1 Asia Biosimilar Revenue by Type (2019-2024)
11.2.2 Asia Biosimilar Revenue by Type (2025-2030)
11.3 Asia Biosimilar Revenue Share by Type (2019-2030)
11.4 Asia Biosimilar Revenue by Application (2019-2030)
11.4.1 Asia Biosimilar Revenue by Application (2019-2024)
11.4.2 Asia Biosimilar Revenue by Application (2025-2030)
11.5 Asia Biosimilar Revenue Share by Application (2019-2030)
11.6 Asia Biosimilar Revenue by Country
11.6.1 Asia Biosimilar Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Biosimilar Revenue by Country (2019-2024)
11.6.3 Asia Biosimilar Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Biosimilar Revenue (2019-2030)
12.2 MEALA Biosimilar Revenue by Type (2019-2030)
12.2.1 MEALA Biosimilar Revenue by Type (2019-2024)
12.2.2 MEALA Biosimilar Revenue by Type (2025-2030)
12.3 MEALA Biosimilar Revenue Share by Type (2019-2030)
12.4 MEALA Biosimilar Revenue by Application (2019-2030)
12.4.1 MEALA Biosimilar Revenue by Application (2019-2024)
12.4.2 MEALA Biosimilar Revenue by Application (2025-2030)
12.5 MEALA Biosimilar Revenue Share by Application (2019-2030)
12.6 MEALA Biosimilar Revenue by Country
12.6.1 MEALA Biosimilar Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Biosimilar Revenue by Country (2019-2024)
12.6.3 MEALA Biosimilar Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global Biosimilar Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Biosimilar Monoclonal Antibodies Major Manufacturers
Table 2. Biosimilar Insulin Major Manufacturers
Table 3. Others Major Manufacturers
Table 4. Global Biosimilar Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Cancer Major Manufacturers
Table 6. Immunological Diseases Major Manufacturers
Table 7. Diabetes Major Manufacturers
Table 8. Others Major Manufacturers
Table 9. Biosimilar Industry Trends
Table 10. Biosimilar Industry Drivers
Table 11. Biosimilar Industry Opportunities and Challenges
Table 12. Biosimilar Industry Restraints
Table 13. Global Biosimilar Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Biosimilar Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Biosimilar Market Share by Region (2019-2024)
Table 16. Global Biosimilar Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Biosimilar Market Share by Region (2025-2030)
Table 18. Global Biosimilar Revenue by Players (US$ Million) & (2019-2024)
Table 19. Global Biosimilar Revenue Market Share by Players (2019-2024)
Table 20. Global Biosimilar Key Players Ranking, 2022 VS 2023 VS 2024
Table 21. Global Biosimilar Key Players Headquarters & Area Served
Table 22. Global Biosimilar Players, Product Type & Application
Table 23. Global Biosimilar Players Commercialization Time
Table 24. Global Players Market Concentration Ratio (CR5 and HHI)
Table 25. Global Biosimilar by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 26. Global Biosimilar Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Biosimilar Revenue by Type (2019-2024) & (US$ Million)
Table 28. Global Biosimilar Revenue by Type (2025-2030) & (US$ Million)
Table 29. Global Biosimilar Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 30. Global Biosimilar Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 31. Global Biosimilar Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Biosimilar Revenue by Application (2019-2024) & (US$ Million)
Table 33. Global Biosimilar Revenue by Application (2025-2030) & (US$ Million)
Table 34. Global Biosimilar Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 35. Global Biosimilar Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 36. Qilu Pharmaceutical Company Information
Table 37. Qilu Pharmaceutical Business Overview
Table 38. Qilu Pharmaceutical Biosimilar Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 39. Qilu Pharmaceutical Biosimilar Product Portfolio
Table 40. Qilu Pharmaceutical Recent Development
Table 41. Bio-Thera Company Information
Table 42. Bio-Thera Business Overview
Table 43. Bio-Thera Biosimilar Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 44. Bio-Thera Biosimilar Product Portfolio
Table 45. Bio-Thera Recent Development
Table 46. Zhejiang Hisun Company Information
Table 47. Zhejiang Hisun Business Overview
Table 48. Zhejiang Hisun Biosimilar Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 49. Zhejiang Hisun Biosimilar Product Portfolio
Table 50. Zhejiang Hisun Recent Development
Table 51. Shanghai Henlius Company Information
Table 52. Shanghai Henlius Business Overview
Table 53. Shanghai Henlius Biosimilar Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 54. Shanghai Henlius Biosimilar Product Portfolio
Table 55. Shanghai Henlius Recent Development
Table 56. Innovent Biologics Company Information
Table 57. Innovent Biologics Business Overview
Table 58. Innovent Biologics Biosimilar Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 59. Innovent Biologics Biosimilar Product Portfolio
Table 60. Innovent Biologics Recent Development
Table 61. Jiangsu Hengrui Company Information
Table 62. Jiangsu Hengrui Business Overview
Table 63. Jiangsu Hengrui Biosimilar Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 64. Jiangsu Hengrui Biosimilar Product Portfolio
Table 65. Jiangsu Hengrui Recent Development
Table 66. Gan&Lee Company Information
Table 67. Gan&Lee Business Overview
Table 68. Gan&Lee Biosimilar Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 69. Gan&Lee Biosimilar Product Portfolio
Table 70. Gan&Lee Recent Development
Table 71. Tonghua Dongbao Company Information
Table 72. Tonghua Dongbao Business Overview
Table 73. Tonghua Dongbao Biosimilar Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 74. Tonghua Dongbao Biosimilar Product Portfolio
Table 75. Tonghua Dongbao Recent Development
Table 76. United Laboratory Company Information
Table 77. United Laboratory Business Overview
Table 78. United Laboratory Biosimilar Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 79. United Laboratory Biosimilar Product Portfolio
Table 80. United Laboratory Recent Development
Table 81. 3SBIO Company Information
Table 82. 3SBIO Business Overview
Table 83. 3SBIO Biosimilar Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 84. 3SBIO Biosimilar Product Portfolio
Table 85. 3SBIO Recent Development
Table 86. Luye Pharma Company Information
Table 87. Luye Pharma Business Overview
Table 88. Luye Pharma Biosimilar Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. Luye Pharma Biosimilar Product Portfolio
Table 90. Luye Pharma Recent Development
Table 91. North America Biosimilar Revenue by Type (2019-2024) & (US$ Million)
Table 92. North America Biosimilar Revenue by Application (2019-2024) & (US$ Million)
Table 93. North America Biosimilar Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 94. North America Biosimilar Revenue by Country (2019-2024) & (US$ Million)
Table 95. North America Biosimilar Revenue by Country (2025-2030) & (US$ Million)
Table 96. Europe Biosimilar Revenue by Type (2019-2024) & (US$ Million)
Table 97. Europe Biosimilar Revenue by Application (2019-2024) & (US$ Million)
Table 98. Europe Biosimilar Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 99. Europe Biosimilar Revenue by Country (2019-2024) & (US$ Million)
Table 100. Europe Biosimilar Revenue by Country (2025-2030) & (US$ Million)
Table 101. China Biosimilar Revenue by Type (2019-2024) & (US$ Million)
Table 102. China Biosimilar Revenue by Application (2019-2024) & (US$ Million)
Table 103. Asia Biosimilar Revenue by Type (2019-2024) & (US$ Million)
Table 104. Asia Biosimilar Revenue by Application (2019-2024) & (US$ Million)
Table 105. Asia Biosimilar Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 106. Asia Biosimilar Revenue by Country (2019-2024) & (US$ Million)
Table 107. Asia Biosimilar Revenue by Country (2025-2030) & (US$ Million)
Table 108. MEALA Biosimilar Revenue by Type (2019-2024) & (US$ Million)
Table 109. MEALA Biosimilar Revenue by Application (2019-2024) & (US$ Million)
Table 110. MEALA Biosimilar Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 111. MEALA Biosimilar Revenue by Country (2019-2024) & (US$ Million)
Table 112. MEALA Biosimilar Revenue by Country (2025-2030) & (US$ Million)
Table 113. Research Programs/Design for This Report
Table 114. Authors List of This Report
Table 115. Secondary Sources
Table 116. Primary Sources
List of Figures
Figure 1. Biosimilar Product Picture
Figure 2. Global Biosimilar Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Biosimilar Market Size Share 2019 VS 2023 VS 2030
Figure 4. Biosimilar Monoclonal Antibodies Picture
Figure 5. Biosimilar Insulin Picture
Figure 6. Others Picture
Figure 7. Global Biosimilar Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 8. Global Biosimilar Market Size Share 2019 VS 2023 VS 2030
Figure 9. Cancer Picture
Figure 10. Immunological Diseases Picture
Figure 11. Diabetes Picture
Figure 12. Others Picture
Figure 13. Global Biosimilar Market Size (US$ Million) & (2019-2030)
Figure 14. Global Biosimilar Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Biosimilar Market Share by Region: 2019 VS 2023 VS 2030
Figure 16. Global Biosimilar Players Revenue Share Top 10 and Top 5 in 2023
Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 18. Global Biosimilar Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Biosimilar Revenue Market Share 2019 VS 2023 VS 2030
Figure 20. Global Biosimilar Revenue Market Share by Type (2019-2030)
Figure 21. Global Biosimilar Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Biosimilar Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 23. Global Biosimilar Revenue Market Share by Application (2019-2030)
Figure 24. North America Biosimilar Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Biosimilar Revenue by Type (2025-2030) & (US$ Million)
Figure 26. North America Biosimilar Revenue Share by Type (2019-2030)
Figure 27. North America Biosimilar Revenue by Application (2025-2030) & (US$ Million)
Figure 28. North America Biosimilar Revenue Share by Application (2019-2030)
Figure 29. North America Biosimilar Revenue Share by Country (2019-2030)
Figure 30. United States Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Canada Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 32. Europe Biosimilar Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 33. Europe Biosimilar Revenue by Type (2025-2030) & (US$ Million)
Figure 34. Europe Biosimilar Revenue Share by Type (2019-2030)
Figure 35. Europe Biosimilar Revenue by Application (2025-2030) & (US$ Million)
Figure 36. Europe Biosimilar Revenue Share by Application (2019-2030)
Figure 37. Europe Biosimilar Revenue Share by Country (2019-2030)
Figure 38. Germany Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. France Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. U.K. Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Italy Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Russia Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Nordic Countries Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. China Biosimilar Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 45. China Biosimilar Revenue by Type (2025-2030) & (US$ Million)
Figure 46. China Biosimilar Revenue Share by Type (2019-2030)
Figure 47. China Biosimilar Revenue by Application (2025-2030) & (US$ Million)
Figure 48. China Biosimilar Revenue Share by Application (2019-2030)
Figure 49. Asia Biosimilar Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 50. Asia Biosimilar Revenue by Type (2025-2030) & (US$ Million)
Figure 51. Asia Biosimilar Revenue Share by Type (2019-2030)
Figure 52. Asia Biosimilar Revenue by Application (2025-2030) & (US$ Million)
Figure 53. Asia Biosimilar Revenue Share by Application (2019-2030)
Figure 54. Asia Biosimilar Revenue Share by Country (2019-2030)
Figure 55. Japan Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. South Korea Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. India Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. Australia Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. China Taiwan Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Southeast Asia Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. MEALA Biosimilar Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 62. MEALA Biosimilar Revenue by Type (2025-2030) & (US$ Million)
Figure 63. MEALA Biosimilar Revenue Share by Type (2019-2030)
Figure 64. MEALA Biosimilar Revenue by Application (2025-2030) & (US$ Million)
Figure 65. MEALA Biosimilar Revenue Share by Application (2019-2030)
Figure 66. MEALA Biosimilar Revenue Share by Country (2019-2030)
Figure 67. Mexico Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. South Korea Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Brazil Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Israel Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Argentina Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Colombia Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Turkey Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Saudi Arabia Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. UAE Biosimilar Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Years Considered
Figure 77. Research Process
Figure 78. Key Executives Interviewed
